Françoise J. Roquet-Banères

Dr. Françoise J. Roquet-Banères

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 September 2021 in Disease Models & Mechanisms
Verified
Journal Article
Open access
PDF file
Matt JohansenMatt Johansen
Matt Johansen
MAMatthéo Alcaraz
Matthéo Alcaraz
RDRebekah M. Dedrick
Rebekah M. Dedrick
FRFrançoise J. Roquet-Banères
Françoise J. Roquet-Banères
CHClaire Hamela
Claire Hamela
LKLaurent Kremer
Laurent Kremer
Infection by multidrug-resistant Mycobacterium abscessus is increasingly prevalent in cystic fibrosis (CF) patients, leaving clinicians with few therapeutic options. A compassionate study showed the clinical improvement of a CF patient with a disseminated M. abscessus (GD01) infection, following injection of a phage cocktail, including phage Muddy. Broadening the use of phage therapy in patients as a potential antibacterial alternative necessitates the development of biological models to improve the reliability and successful prediction of phage therapy in the clinic. Herein, we demonstrate that Muddy very efficiently lyses GD01 in vitro, an effect substantially increased with standard drugs. Remarkably, this cooperative activity was retained in an M. abscessus model of infection in CFTR-depleted zebrafish, associated with a striking increase in larval survival and reduction in pathological signs. The activity of Muddy was lost in macrophage-ablated larvae, suggesting that successful phage therapy relies on functional innate immunity. CFTR-depleted zebrafish represent a practical model to rapidly assess phage treatment efficacy against M. abscessus isolates, allowing the identification of drug combinations accompanying phage therapy and treatment prediction in patients. This article has an associated First Person interview with the first author of the paper.

9 October 2024 in Royal Society Open Science
Verified
Journal Article
Open access
­­­ ­sHekhar
­ ­sHekhar
FRFrançoise J. Roquet-Banères
Françoise J. Roquet-Banères
AAAmit Anand
Amit Anand
LKLaurent Kremer
Laurent Kremer
VKVipan Kumar
Vipan Kumar
A set of alkyl-/1H-1,2,3-triazole-based dimers was strategically designed and synthesized to evaluate their in vitro anti-mycobacterial activities against Mycobacterium tuberculosis and the non-tuberculous Mycobacterium abscessus strains. Systematic variations in the nature (alkyl/1H-1,2,3-triazole) and positioning of the linker were implemented based on the docking scores observed in the binding sites identified in the crystal structures of InhA from M. tuberculosis and M. abscessus . However, the in vitro evaluation results revealed that the synthesized compounds did not exhibit inhibitory effects on the growth of mycobacteria, even at the highest tested concentrations. The elevated lipophilicity values determined through ADMET studies for these synthesized dimers might be a contributing factor to their poor activity profiles.

6 August 2025 in Antibiotics
Verified
Journal Article
Open access
PDF file
ABAntonio Broncano-Lavado
Antonio Broncano-Lavado
JAJohn Jairo Aguilera-Correa
John Jairo Aguilera-Correa
FRFrançoise J. Roquet-Banères
Françoise J. Roquet-Banères
LKLaurent Kremer
Laurent Kremer
AMAranzazu Mediero
Aranzazu Mediero
MGMeritxell García-Quintanilla
Meritxell García-Quintanilla
Background/Objectives: Mycobacterium abscessus is an opportunistic pathogen causing infections mainly in patients with immunosuppression and chronic pulmonary pathologies. Extended treatment periods are needed to tackle this pathogen, bacterial eradication is rare, and recurrence can take place with time. New alternative treatments are being investigated, such as bacteriophage therapy. This work describes the characterization of the mycobacteriophage P3MA, showing its ability to infect clinical and standard M. abscessus strains. Methods: Phylogenetic analysis, electron microscopy, growth curves, biofilm assays, checkerboard, and granuloma-like medium studies were performed. Results: P3MA inhibited the growth of clinical samples in both planktonic and biofilm states as well as in a granuloma-like model. The study of the interaction with antibiotics revealed that P3MA exhibited an antagonistic effect combined with clarithromycin, indifference with amikacin, and synergy with imipenem. Conclusions: All these results suggest that, after genetic engineering, P3MA could be a promising candidate for phage therapy in combination with imipenem, including lung infections.

12 June 2025 in Microbiology Resource Announcements
Verified
Journal Article
Open access
ABAntonio Broncano-Lavado
Antonio Broncano-Lavado
FRFrançoise J. Roquet-Banères
Françoise J. Roquet-Banères
LKLaurent Kremer
Laurent Kremer
DRDaniel A. Russell
Daniel A. Russell
DJDeborah Jacobs-Sera
Deborah Jacobs-Sera
MGMeritxell García-Quintanilla
Meritxell García-Quintanilla
Mycobacteriophage P3MA is a newly isolated bacteriophage recovered from the Manzanares River in Madrid, Spain, using Mycobacterium abscessus 330 as a host strain. P3MA has a 41,151 bp genome with 63 predicted protein-coding genes and is closely related to prophages identified in several M. abscessus genomes grouped in Cluster HB.

2 May 2024 in Microbiology Spectrum
Verified
Journal Article
Open access
YBYves-Marie Boudehen
Yves-Marie Boudehen
WDWassim Daher
Wassim Daher
FRFrançoise J. Roquet-Banères
Françoise J. Roquet-Banères
LKLaurent Kremer
Laurent Kremer
Mycobacterium abscessus, an emerging pathogen responsible for severe pulmonary infections in cystic fibrosis patients, displays either a smooth (S) or a rough (R) morphotype. Infections with M. abscessus R are associated with increased pathogenicity in animal models and humans. While the S-to-R transition correlating with reduced glycopeptidolipid (GPL) production is well-documented, the recent screening of a transposon library revealed additional gene candidates located outside of the GPL locus involved in this transition. These genes include MAB_1470c , encoding the putative lipoprotein peptidase LpqM. However, experimental confirmation of the implication of this gene in the morphotype switch is lacking. Herein, we re-examined the role of MAB_1470c , and its homolog MAB_1466c , in colonial morphotype changes by generating unmarked deletion mutants in M. abscessus S. Our results indicate that the morphotype of these mutants stayed smooth in different media. Unexpectedly, the intracellular growth of Δ MAB_1470c and Δ MAB_1466c in THP-1 macrophages was significantly reduced as compared to the parental S strain, and these defects were rescued upon complementation with their corresponding genes. Strikingly, the intracellular survival defect was further exacerbated in a mutant lacking both MAB_1470c and MAB_1466c genes. This implies that, despite their primary sequence relatedness, the two proteins are not functionally redundant. Collectively, this suggests that these two LpqM-related lipoproteins are unlikely to be involved in the S-to-R transition but are key players for intramacrophage survival of M. abscessus . IMPORTANCE: Mycobacterium abscessus causes persistent infections in patients with underlying pulmonary diseases, resulting in progressive lung function deterioration. The rough (R) morphotype is well-established as associated with chronic and more aggressive infections in patients. In this study, we individually and simultaneously deleted the MAB_1470c and MAB_1466c genes in M. abscessus S, without observing changes in colony morphotypes. However, these mutants exhibited a severe impairment in their ability to survive within human macrophages, highlighting the critical role of these two lipoproteins in M. abscessus virulence.

Verified
Journal Article
Open access
PDF file
MKMukanda Gedeon Kadima
Mukanda Gedeon Kadima
Vinayak SinghVinayak Singh
Vinayak Singh
GKGobind Kumar
Gobind Kumar
SMSahil Mishra
Sahil Mishra
PSPule Seboletswe
Pule Seboletswe
PSParvesh Singh
Parvesh Singh
A series of INH–pyrazole molecular hybrids (6a–o) was synthesized and evaluated for in vitro anti-tubercular activity against drug-susceptible, multidrug-resistant (MDR), and extensively drug-resistant (XDR) Mycobacterium tuberculosis strains, alongside their corresponding precursors (4a–o), using isoniazid (INH) as the reference drug. Overall, the hybrid compounds exhibited inhibitory activity comparable to or exceeding that of INH against the drug-susceptible strain. Among the series, compounds 6a, 6d–6f, and 6m demonstrated the highest potency, with a minimum inhibitory concentration (MIC) of 0.9 µM, corresponding to an approximately 4.3-fold enhancement relative to INH. Compounds 6b,c, 6g–i, and 6l,m also showed noticeable activity (MIC = 1.95 µM), representing an approximate twofold improvement over INH and significantly outperforming their respective precursors. Notably, compound 6o exhibited enhanced activity against the XDR strain (MIC = 121 µM), reflecting an approximately 2.8-fold improvement compared to precursor 4o (MIC > 341 µM), thereby highlighting the advantage of molecular hybridization. However, all compounds displayed diminished activity relative to INH against the resistant strains. Against the MDR strain, compounds 4h, 6e, and 6g displayed measurable activity, with MIC values of 76, 125, and 112 µM, respectively. Cytotoxicity assessment using THP-1 human monocytic cells revealed low toxicity, with all tested compounds maintaining acceptable cell viability at 10 µg/mL. In addition, in silico ADME analysis indicated that the hybrid molecules comply with key drug-likeness criteria. Collectively, these findings suggest that INH–pyrazole hybrids represent promising lead scaffolds for the development of next-generation anti-tubercular agents.